agency in a timely fashion. The Corrections and Removal regulation, 21 CFR Part 806, was
promulgated to meet these provisions and took effect on May 18, 1998. The regulation
initially required manufacturers, distributors, and importers to report promptly to the FDA
any corrections or removals of devices being undertaken to reduce risk to health. The Food
and Drug Administration Modernization Act (FDAMA) of 1997 amended section 519(g) of
the Act (21 U.S.C. 360i(g)) to eliminate the requirement for distributors to report corrections
and removals. The revised 21 CFR Part 806 was published in the Federal Register and
became effective December 21, 1998 (63 FR 42229). The regulation, 21 CFR Part 806,
requires that device manufacturers and importers report promptly to the FDA any correction
or removal of a device undertaken: (1) to reduce a risk to health posed by the device; or (2) to
remedy a violation of the act caused by a device which may present a risk to health. Device
manufacturers and importers are also required to keep records of all corrections and
removals, including those not required to be reported to the FDA under Section 519(g)(1)(B)
of the Act.
6. THE REGISTRATION AND LISTING REGULATION (21 CFR Part 807)
The Registration and Listing regulation, 21 CFR Part 807, was promulgated to meet
requirements of the Medical Device Amendments of 1976 (42 FR 42526). Owners or
operators of establishments that are involved in the production and distribution of medical
devices intended for use in the United States are required to register annually with the FDA,
and as general rule, establishments required to register with the FDA are also required to list
the devices they make and the activities that are performed on those devices. Registration and
listing provide the FDA with the location of medical device establishments and the devices
manufactured at those establishments.
Who Must Register, List and Pay the Fee | FDA describes the requirements for registration
and listing based on the type of activity performed at that establishment, including which
types of activities require payment of the establishment registration fee.
7. UNIQUE DEVICE IDENTIFICATION (UDI) SYSTEM (21 CFR PART 801
SUBPART B AND 21 CFR PART 830)
The FDA established the UDI system to adequately identify medical devices sold in the
United States, from manufacturing through distribution, under section 519(f) of the F D&C
Act. Benefits of the UDI system include, but are not limited to, simplifying the integration of
device use; providing for more rapid identification of medical devices with adverse events;
providing for more rapid development of solutions to reported problems and efficient
resolution of device recalls; and providing better focused and more effective FDA safety
communications. In the UDI final rule (78 FR 58785), device labelers (typically
manufacturers) are required to: 1) include a UDI, issued under an FDA-accredited issuing
agency’s UDI system, on device labels, device packages, and in some cases, directly marked
on the device; and 2) submit device information to the Global Unique Device Identification
Database (GUDID). AccessGUDID is a searchable database of device information
(including, for instance, device identifier on the label, device name, premarket submission
numbers) available to the public. The Unique Device Identifier System: Frequently Asked